Clinical trial · Interventional
SB17170 Phase 1 Clinical Trial in Solid Tumors
An Open-label, Multicenter, Phase 1 Clinical Trial to Evaluate MTD, Safety, PK/PD and Preliminary Anti-tumor Activity of SB17170 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Failed Standard of Care
NCT05522868CI-TRIAL-00097609recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SB17170 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Cohort 1
- description
- SB17170 initial dose: 300 mg/d per day, 3 to 6 subjects per cohort
- interventionNames
- Drug: SB17170
- type
- OTHER
- label
- Cohort 2
- description
- SB17170 dose: 600 mg/d per day, 3 to 6 subjects per cohort
- interventionNames
- Drug: SB17170
- type
- OTHER
- label
- Cohort 3
- description
- SB17170 dose: 1000 mg/d per day, 3 to 6 subjects per cohort
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * A patient with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors. * A person who has failed the known standard of care or has developed resistance to the standard of care and no longer has applicable standard of care * A patient with at least one measurable lesion according to the RECIST v1.1 criteria. * A person with Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. * Those with an expected survival period of 3 months or more at the discretion of of the investigator. Exclusion Criteria: * A patient who has received drugs targeting High Mobility Group Box 1 (HMGB1). * A patient who has received or is undergoing chemotherapy (including chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted therapy, biological products, and tumor embolization) within 28 days from the first administration date of the investigational drug. * A person who needs to take contraindicated drugs or is expected to take them during the study period.
References
Publications (0)
Data not yet available
No reference posted for this study.